Patents by Inventor James D. Marks

James D. Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7332580
    Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: February 19, 2008
    Assignees: The Regents of the University of California, Fox Chase Cancer Center
    Inventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
  • Patent number: 7332585
    Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: February 19, 2008
    Assignees: The Regents of the California University, Fox Chase Cancer Center
    Inventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
  • Patent number: 7244826
    Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: July 17, 2007
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Marie Alix Poul
  • Patent number: 7045283
    Abstract: This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: May 16, 2006
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Ulrik B. Nielson, Dimitri B. Kirpotin
  • Patent number: 6794128
    Abstract: This invention provides methods of selecting antibodies that are internalized into target cells. The methods generally involve contacting target cells with one or more members of an antibody phage display library. The members of the phage display library are also contacted with cells of a subtractive cell line. The target cells are then washed to remove the subtractive cell line cells and members of the phage display library that are non-specifically bound or weakly bound to the target cells. The target cells are cultured under conditions where members of the phage display library can be internalized if bound to an internalizing marker and internalized members of the phage display library are then identified.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: September 21, 2004
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Marie Alix Poul, Baltazar Becerril
  • Publication number: 20040175385
    Abstract: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Application
    Filed: August 1, 2003
    Publication date: September 9, 2004
    Applicant: The Regents of the University of Carlifornia
    Inventors: James D. Marks, Peter Amersdorfer
  • Publication number: 20040071696
    Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
    Type: Application
    Filed: April 4, 2003
    Publication date: April 15, 2004
    Applicants: The Regents of the University of California, The Fox Chase Cancer Center
    Inventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
  • Publication number: 20030154106
    Abstract: A system and method for renewing prescriptions is provided. Visitors to a web site, who may or may not register, are given the opportunity to request renewals of drug prescriptions on the web site. Visitors are prompted to enter information relevant to the renewal. The web site in one alternative maintains a database of visitors medical and/or contact information and issues a membership ID or Plan ID. In an alternative the web site may offer an opt-in buyer's club for obtaining discounts or information about prescriptions. The web site, in one alternative, maintains a database of information about doctors who are registered with the web site. The visitor may then select a doctor from a list and use the site to request a prescription renewal from that doctor. The web site uses information entered by the visitor, or information previously provided by the visitor accessed from the web site's database, to format a fax or email to the doctor requesting a renewal of the visitors prescription.
    Type: Application
    Filed: January 24, 2003
    Publication date: August 14, 2003
    Applicant: Body Health Resources Corporation
    Inventor: James D. Marks
  • Publication number: 20030033532
    Abstract: A system and method for on-line formation of buyer's clubs, in particular, for the purchase of pharmaceutical goods, e.g., drugs, vitamins and/or herbs. Visitors of a web site are prompted while completing registration information whether to opt in to participate in a buyer's club. At least some of the registration information provided by those users that have chosen to opt in to participate in the buyer's club is transmitted to a Pharmaceutical Benefits Manager (PBM) and/or pharmacy that, in turn, enters into agreements with drug manufacturers to offer the pharmaceutical goods at discount prices. Member utilization information is generated by the PBM for each participant that purchases through the buyer's club. This member utilization information is transmitted from the PBM to the server.
    Type: Application
    Filed: August 9, 2002
    Publication date: February 13, 2003
    Applicant: BODY HEALTH RESOURCES CORPORATION
    Inventor: James D. Marks
  • Patent number: 6512097
    Abstract: This invention provides novel chimeric molecules that specifically binds a tumor cell bearing a c-erbB-2. The chimeric molecules comprise an effector molecule attached to a C6 antibody that specifically binds to c-erbB-2. The chimeric molecules can specifically target and deliver effector molecules to cells overexpressing c-erb-B2.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: January 28, 2003
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Robert Schier
  • Publication number: 20020182643
    Abstract: This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.
    Type: Application
    Filed: October 16, 2001
    Publication date: December 5, 2002
    Inventors: James D. Marks, Ulrik B. Nielsen, Dimitri B. Kirpotin
  • Publication number: 20020076727
    Abstract: Disclosed are products and methods to facilitate the identification of compounds that are capable of interacting with biological macromolecules of interest, especially when such macromolecules are attached to a support surface in microarray. Aspects of the invention concern attachment chemistry, peptide labeling, antibody preparation, applications and so on.
    Type: Application
    Filed: August 3, 2001
    Publication date: June 20, 2002
    Inventors: Michael H. Cardone, Ulrik Nielsen, Gavin MacBeath, James D. Marks, Peter Sorger, Anthony Sinsky
  • Patent number: 5977322
    Abstract: This invention provides novel human antibodies that specifically bind to human c-erbB-2. In one embodiment, the antibodies are single chain antibodies initially developed by phage display against a c-erbB-2 target. The resulting antibodies (designated C6 antibodies) show improved specificity and affinity for c-erbB-2. In addition, since the C6 antibodies are both relatively small and fully human they are less immunogenic in humans than other (e.g., full-size or chimeric) anti-c-erbB-2 antibodies. The C6 antibodies may be used alone or as components of chimeric molecules that specifically target and deliver effector molecules to cells overexpressing c-erbB-2.
    Type: Grant
    Filed: June 13, 1996
    Date of Patent: November 2, 1999
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Robert Schier